New drug offers hope for celiac patients still suffering despite Gluten-Free diet
NCT ID NCT04424927
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 29 times
Summary
This study tested an experimental drug called PRV-015 in 388 adults with non-responsive celiac disease—meaning they still have symptoms even after following a strict gluten-free diet. The goal was to see if the drug could reduce belly pain, bloating, cramping, and gas compared to a placebo. Participants took the drug or a placebo for 24 weeks while continuing their gluten-free diet. The study is now complete, and results will help determine if PRV-015 can offer additional symptom relief for this challenging condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site
Los Angeles, California, 90036, United States
-
Clinical Site
Ventura, California, 93003, United States
-
Clinical Site
Denver, Colorado, 80209, United States
-
Clinical Site
Leesburg, Florida, 34748, United States
-
Clinical Site
Tampa, Florida, 33613, United States
-
Clinical Site
Winter Park, Florida, 32789, United States
-
Clinical Site
Chicago, Illinois, 60637, United States
-
Clinical Site
Boston, Massachusetts, 02111, United States
-
Clinical Site
Chesterfield, Michigan, 48047, United States
-
Clinical Site
Rochester, Minnesota, 55905, United States
-
Clinical Site
Morristown, New Jersey, 07960, United States
-
Clinical Site
New Windsor, New York, 12553, United States
-
Clinical Site
Raleigh, North Carolina, 27607, United States
-
Clinical Site
Philadelphia, Pennsylvania, 19104, United States
-
Clinical Site
Uniontown, Pennsylvania, 14401, United States
-
Clinical Site
Warwick, Rhode Island, 02886, United States
-
Clinical Site
Nashville, Tennessee, 37212, United States
-
Clinical Site
Garland, Texas, 75044, United States
-
Clinical Site
West Jordan, Utah, 84088, United States
-
Clinical Site
Bellevue, Washington, 98004, United States
-
Clinical Site
Tacoma, Washington, 98405, United States
-
Clinical Site
Hamilton, Ontario, L8S4K1, Canada
-
Clinical Site
Amsterdam, 1105 AZ, Netherlands
-
Clinical Site
Seville, Andalusia, 41013, Spain
-
Clinical Site
León, Castille and León, 24071, Spain
-
Clinical Site
Madrid, 28034, Spain
-
Clinical Site
Madrid, 28041, Spain
-
Clinical Site
Madrid, 28222, Spain
-
Clinical Trial Site
Northbrook, Illinois, 60062, United States
-
Clinical Trial Site
Chevy Chase, Maryland, 20815, United States
-
Clinical Trial Site
Brooklyn, New York, 11235, United States
-
Clinical Trial Site
New York, New York, 10032, United States
-
Clinical Trial Site
Dublin, Ohio, 43016, United States
-
Clinical Trial Site
North Charleston, South Carolina, 29405, United States
-
Clinical Trial Site
Cedar Park, Texas, 78613, United States
-
Clinical Trial Site
Terrassa, Catalonia, 082211, Spain
-
Clinical Trial Site
Girona, 17007, Spain
-
Clinical Trial Site
Lleida, 25196, Spain
Conditions
Explore the condition pages connected to this study.